Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016810 | 0.87 | MTNR1A (0.42) | MTNR1ALMNAKDM4ENPSR1MAPK1 | |
| SCHEMBL12544774 | 0.82 | KMT2A (0.46) | MTNR1ALMNAKDM4ENPSR1ALDH1A1 | |
| SCHEMBL12544776 | 0.82 | KMT2A (0.46) | MTNR1ALMNAKDM4ENPSR1ALDH1A1 | |
| SCHEMBL12630208 | 0.82 | ALDH1A1 (0.43) | MTNR1ALMNAKDM4ENPSR1ALDH1A1 | |
| SCHEMBL15305097 | 0.82 | ALDH1A1 (0.43) | MTNR1ALMNAKDM4ENPSR1ALDH1A1 | |
| SCHEMBL7202817 | 0.81 | MTNR1A (0.66) | MTNR1ALMNATP53 | |
| SCHEMBL15954931 | 0.80 | MTNR1A (0.45) | MTNR1AKDM4ENPSR1ALDH1A1MAPT | |
| SCHEMBL15954930 | 0.80 | MTNR1A (0.45) | MTNR1AKDM4ENPSR1ALDH1A1MAPT | |
| SCHEMBL17928601 | 0.79 | MTNR1A (0.47) | MTNR1AKDM4ENPSR1ALDH1A1MAPT | |
| SCHEMBL14250228 | 0.78 | MTNR1A (0.46) | MTNR1AKDM4ENPSR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG | 2015-03-12 | — | — | US | disclosed |
| US-8927541-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| EP-2513115-B1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| EP-2513115-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073378-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | CBR1, CBR3, C1S | MTNR1A 158/4885LMNA 4019/4885KDM4E 3896/4885 |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | TREH, MRPL21, SPOUT1 | MTNR1A 2325/4885LMNA 3459/4885KDM4E 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.